Interpretation and comments of 2022 American Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease
Thyroid eye disease(TED)is an autoimmune disease characterized by infiltrative lesions of the retroocular and periorbital tissues,which can seriously affect the quality of life,physical and mental health,and increase the economic burden of families and society.Teprotumumab became the first drug ap-proved by the Food and Drug Administration(FDA)to for the treatment of TED in 2020.In September 2022,Professor Douglas,an internationally renowned expert in TED and oculoplastic medicine,led the team and wrote the first expert consensus on the treatment of TED with teprotumumab.This consensus describes not only the indications and contraindications of teprotumumab therapy,but also patient evaluation,treat-ment plan,safety,follow-up monitoring,etc.,providing practical guidance and reference for clinicians.
万方数据
维普
